Table 6.
Comparison of the literatures for helical tomotherapy in patients with unresectable hepatocellular carcinoma
| Reference | No. | Fraction size (Gy) | Total dose (Gy) | Target of RT | Response (%) | Median Survival (months) | RILD (%) | Grade III toxicity | Combined therapy |
|---|---|---|---|---|---|---|---|---|---|
| McIntosh [19] | 20 | 2.5 | 50 | PVTT(+) 40 % | PR 6.2 | 9.6 | N/A | UGI bleeding 1/20 | Capecitabine |
| PVTT(−) 60 % | SD 87.5 | ||||||||
| Chi [34] | 23 | 2.5–4.5 | 52.5 (median) | N/A | CR 8.6 | 16 | 1/23 | UGI bleeding 2/23 | Sunitinib |
| PR 65.4 | Hematology 6/23 | ||||||||
| Kim [14] | 35 | 4.5–6 | 50 (range, 45–60) | PVTT(+) 100 % | CR 14.3 | 12.9 | 0/35 | GI bleeding 2/35 | Capecitabine |
| PR 28.6 | Responder 13.9 | Hematology 3/35 | |||||||
| Non-responder 6.9 | |||||||||
| Kong [15] | 20 | 1.8–4 | 50–57.5 (range, 30–60) | PVTT(+) 36.4 % | CR 18.2 | 14.4 | 1/20 | None | None |
| PVTT(−) 63.6 % | PR 54.5 | Responder 87.8a | |||||||
| Non-responder 65.6a | |||||||||
| Current study | 38 | 1.8–2.4 | 54 (range, 46–71.8) | PVTT(+) 63.2 % | CR 5.2 | 12.6 | 1/38 | 1/38 | None |
| PVTT(−) 36.5 % | PR 47.4 | Responder 27.8 | |||||||
| Non-responder 6.2 |
RT radiation therapy, PVTT portal vein tumor thrombus, N/A no data, CR complete response, PR partial response, SD stable disease, RILD radiation-induced liver disease, GI gastrointestinal
a1-year overall survival rate (%)